Deeply committed to aortic treatment
In the constant pursuit to improve outcomes, we join in service with physicians to engineer powerful products and form empowering partnerships.
The only AAA device that is infrarenal by design, intended to help mitigate the risks associated with suprarenal fixation devices.
“Stent grafts with active fixation below the renal arteries as well as oversizing by less than 10% seem to have the least effect on aortic neck degeneration over time…”
Evolving TEVAR:
Vascular Surgeon shares his experience with TEVAR device
Preservation matters: Introduced the first and only FDA approved iliac branch solution
Continued Aortic Innovation
We have multiple clinical and investigational trials in process, supporting a robust aortic pipeline.
Thoracoabdominal Breakthrough Device designation
FDA Approval: first flexible, off-the-shelf single-branch thoracic endoprosthesis for patients requiring zone 2 treatment
Our commitment to lifelong innovation
- Kay B. Active stent-graft fixation below the renal arteries may have the least effect on aortic neck degeneration, study finds. Vascular Specialist -Society for Vascular Surgery (SVS) website. Posted November 17, 2020. Accessed December 2, 2020.
* Three year follow-up of U.S. IDE Clinical Trial for all patients from primary enrollment (n = 63)
22595161-EN